Quince Therapeutics logo

Quince TherapeuticsNASDAQ: QNCX

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

09 May 2019

Next earnings report:

14 November 2024

Last dividends:

N/A

Next dividends:

N/A
$64.91 M
-87%vs. 3y high
38%vs. sector
-vs. 3y high
-vs. sector
-64%vs. 3y high
49%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | Fri, 01 Nov 2024 23:55:04 GMT
$1.50-$0.14(-8.54%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

QNCX Latest News

Quince Therapeutics to Participate at Upcoming Investor Conferences
https://www.businesswire.com/news/home/20241014846322/en/Quince-Therapeutics-to-Participate-at-Upcoming-Investor-Conferences/14 October 2024 Sentiment: POSITIVE

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX #biotech--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced that management will present at three upcoming investor conferences: 2024 Maxim Healthcare Virtual Summit – Quince's Chief Executive Officer and Chief Medical Officer Dirk Thye, M.D., will participate in a fireside chat on Thursday, October 17, 2024 beginning at 3.

Don't Know Much Biology? Tips for Picking Microcap Biotech, Pharma
Zacks Investment Research07 March 2024 Sentiment: POSITIVE

Two microcap biotech stocks to consider for the science-challenged among us.

What type of business is Quince Therapeutics?

Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.

What sector is Quince Therapeutics in?

Quince Therapeutics is in the Healthcare sector

What industry is Quince Therapeutics in?

Quince Therapeutics is in the Biotechnology industry

What country is Quince Therapeutics from?

Quince Therapeutics is headquartered in United States

When did Quince Therapeutics go public?

Quince Therapeutics initial public offering (IPO) was on 09 May 2019

What is Quince Therapeutics website?

https://www.quincetx.com

Is Quince Therapeutics in the S&P 500?

No, Quince Therapeutics is not included in the S&P 500 index

Is Quince Therapeutics in the NASDAQ 100?

No, Quince Therapeutics is not included in the NASDAQ 100 index

Is Quince Therapeutics in the Dow Jones?

No, Quince Therapeutics is not included in the Dow Jones index

When was Quince Therapeutics the previous earnings report?

No data

When does Quince Therapeutics earnings report?

The next expected earnings date for Quince Therapeutics is 14 November 2024